ReviewJournal of cellular and molecular medicine2015
Translational aspects of cardiac cell therapy.
Review in Journal of cellular and molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Fabrication and Characterization Techniques of In Vitro 3D Tissue Models.International journal of molecular sciences · 2023Review
- Trophoblast Stem-Cell-Derived Exosomes Alleviate Cardiotoxicity of Doxorubicin via Improving Mfn2-Mediated Mitochondrial Fusion.Cardiovascular toxicology · 2023Article
- Autophagy stimulation delayed biological aging and decreased cardiac differentiation in rabbit mesenchymal stem cells.Journal of cardiovascular and thoracic research · 2021Article
- Experimental Single-Platform Approach to Enhance the Functionalization of Magnetically Targetable Cells.ACS applied bio materials · 2020Article
- Apolipoprotein A-I Supports MSCs Survival under Stress Conditions.International journal of molecular sciences · 2020Article
- Apoptosis of mesenchymal stem cells is regulated byChronic diseases and translational medicine · 2019Article
- Effect of miR-134 against myocardial hypoxia/reoxygenation injury by directly targeting NOS3 and regulating PI3K/Akt pathway.Acta cirurgica brasileira · 2019Article
- Cardiosphere-derived cells suppress allogeneic lymphocytes by production of PGE2 acting via the EP4 receptor.Scientific reports · 2018Article
- TGF-β1 combined with Sal-B promotes cardiomyocyte differentiation of rat mesenchymal stem cells.Experimental and therapeutic medicine · 2018Article
- Recent Progress in Stem Cell Modification for Cardiac Regeneration.Stem cells international · 2018Review
- Involment of RAS/ERK1/2 signaling and MEF2C in miR-155-3p inhibition-triggered cardiomyocyte differentiation of embryonic stem cell.Oncotarget · 2017Article
- Granulocyte-Colony Stimulating Factor (G-CSF) Accelerates Wound Healing in Hemorrhagic Shock Rats by Enhancing Angiogenesis and Attenuating Apoptosis.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Preparation and In Vitro Characterization of Magnetized miR-modified Endothelial Cells.Journal of visualized experiments : JoVE · 2017Article
- Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types.NPJ Regenerative medicine · 2017Review
- Optimized protocol for immunostaining of experimental GFP-expressing and human hearts.Histochemistry and cell biology · 2016Article
- Intramyocardial implantation of differentiated rat bone marrow mesenchymal stem cells enhanced by TGF-β1 improves cardiac function in heart failure rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Cell therapy has been intensely studied for over a decade as a potential treatment for ischaemic heart disease. While initial trials using skeletal myoblasts, bone marrow cells and peripheral blood stem cells showed promise in improving cardiac function, benefits were found to be short-lived likely related to limited survival and engraftment of the delivered cells. The discovery of putative cardiac 'progenitor' cells as well as the creation of induced pluripotent stem cells has led to the delivery of cells potentially capable of electromechanical integration into existing tissue. An alternative strategy involving either direct reprogramming of endogenous cardiac fibroblasts or stimulation of resident cardiomyocytes to regenerate new myocytes can potentially overcome the limitations of exogenous cell delivery. Complimentary approaches utilizing combination cell therapy and bioengineering techniques may be necessary to provide the proper milieu for clinically significant regeneration. Clinical trials employing bone marrow cells, mesenchymal stem cells and cardiac progenitor cells have demonstrated safety of catheter based cell delivery, with suggestion of limited improvement in ventricular function and reduction in infarct size. Ongoing trials are investigating potential benefits to outcome such as morbidity and mortality. These and future trials will clarify the optimal cell types and delivery conditions for therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.